Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), TYK2 inhibitors(Tyrosine-protein kinase 2 inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC17H18N4O3 |
InChIKeyZFQNHUSKKDBFHY-GRYCIOLGSA-N |
CAS Registry2222137-79-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammation | NDA/BLA | US | 26 Jan 2020 | |
Chronic Urticaria | Phase 3 | CN | 19 Mar 2024 | |
Rheumatoid Arthritis | Phase 3 | CN | 14 Nov 2023 | |
Plaque psoriasis | Phase 2 | US | 19 Jan 2023 | |
Psoriasis | Phase 2 | CN | - | |
Dermatitis, Atopic | Phase 1 | CN | 10 Jul 2023 | |
Systemic Lupus Erythematosus | IND Approval | CN | 21 Aug 2023 | |
Colitis, Ulcerative | Discovery | US | 30 Dec 2022 |
NCT05133297 (EULAR2023) Manual | Phase 2 | 101 | (gaadniulni) = nlsndochfr seplbcwcvc (mpwitgegzr, 28.42 - 67.58) View more | Positive | 31 May 2023 | ||
(gaadniulni) = jhccviwuyp seplbcwcvc (mpwitgegzr, 47.10 - 83.67) View more |